Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.41 |
| ▸ | NPY4R | P50391 | 11/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.39 |
| ▸ | NPY1R | P25929 | 7/20 | 0.39 |
| ▸ | NPY2R | P49146 | 5/20 | 0.39 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 2/20 | 0.38 |
| ▸ | FNTB | P49356 | 2/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10357149 | 1.00 | NOD1 (0.41) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30197694 | 0.92 | NOD1 (0.40) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29635279 | 0.90 | NPY4R (0.47) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30929896 | 0.90 | NOD1 (0.47) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29678580 | 0.90 | TERT (0.42) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29358945 | 0.89 | NPY4R (0.42) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29358971 | 0.89 | NPY4R (0.42) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL7242707 | 0.89 | NPY4R (0.42) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL7098551 | 0.89 | NPY4R (0.42) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29357342 | 0.89 | NPY4R (0.42) | NOD1NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0167152-B1 | PROTEASE ADSORBENT AND PROCESS FOR PURIFYING TPA UTILIZING THE SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1990-11-14 | — | — | EP | claimed |
| US-20260146247-A1 | Compositions and Methods for Targeted Delivery of CRISPR-CAS Effector Polypeptides and Transgenes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-28 | — | — | US | disclosed |
| US-12624063-B2 | Compositions and methods for modification of target molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260109753-A1 | Syntac Polypeptides and Uses Thereof | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260070959-A1 | T-Cell Modulatory Chimeric Molecules and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12565647-B2 | Compositions and methods for targeted delivery of CRISPR-Cas effector polypeptides and transgenes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-03 | — | — | US | disclosed |
| US-12534722-B2 | Euglobulin-based method for determining the biological activity of defibrotide | GENTIUM S.R.L. (IT) | 2026-01-27 | — | — | US | disclosed |
| US-12529052-B2 | Euglobulin-based method for determining the biological activity of defibrotide | GENTIUM S.R.L. (IT) | 2026-01-20 | — | — | US | disclosed |
| US-20260015381-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | UNIV CALIFORNIA (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260008996-A1 | Compositions and Methods for Modification of Cells | UNIV CALIFORNIA (US) | 2026-01-08 | — | — | US | disclosed |
| CN-114728172-A | Notch receptors with minimal linkers | 加利福尼亚大学董事会 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728174-A | Receptors with heterologous transmembrane domains | 加利福尼亚大学董事会 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728173-A | Novel receptors with heterologous stop transfer sequences for ligand-dependent transcriptional regulation | 加利福尼亚大学董事会 | 2022-07-08 | — | — | CN | disclosed |
| US-11358995-B2 | Compositions and methods of use for treating metabolic disorders | NGM BIOPHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| CN-114599674-A | T cell modulating chimeric molecules and methods of use thereof | 库尔生物制药有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20220153779-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-19 | — | — | US | disclosed |
| CN-106687128-B | Compositions and methods for treating metabolic disorders | NGM生物制药有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20220133797-A1 | NOTCH RECEPTORS WITH HINGE DOMAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-05 | — | — | US | disclosed |
| CN-106573966-B | Compositions and methods for treating metabolic abnormalities | NGM生物制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-11236328-B2 | Euglobulin-based method for determining the biological activity of defibrotide | GENTIUM S.R.L. (IT) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070959-A1 | T-Cell Modulatory Chimeric Molecules and Methods of Use Thereof | ICOS, ICOSLG, CD274 | NOD1 1611/4885NPY4R 899/4885NPY5R 2356/4885 |
| US-20260109753-A1 | Syntac Polypeptides and Uses Thereof | ICOS, CD40LG, CD40 | NOD1 466/4885NPY4R 464/4885NPY5R 501/4885 |
| US-12624063-B2 | Compositions and methods for modification of target molecules | TYR, TH, COMT | NOD1 2801/4885NPY4R 735/4885NPY5R 1220/4885 |
| US-20260015381-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | TH, COMT, TYR | NOD1 1360/4885NPY4R 2246/4885NPY5R 2336/4885 |
| US-20260008996-A1 | Compositions and Methods for Modification of Cells | CD2, CD47, EPCAM | NOD1 3143/4885NPY4R 2604/4885NPY5R 2189/4885 |
| US-12529052-B2 | Euglobulin-based method for determining the biological activity of defibrotide | FGB, PLG, F2 | NOD1 1329/4885NPY4R 3918/4885NPY5R 3688/4885 |
| US-12565647-B2 | Compositions and methods for targeted delivery of CRISPR-Cas effector polypeptides and transgenes | CD4, PBK, HAVCR2 | NOD1 2841/4885NPY4R 2784/4885NPY5R 3078/4885 |
| US-20260146247-A1 | Compositions and Methods for Targeted Delivery of CRISPR-CAS Effector Polypeptides and Transgenes | LNPEP, PRNP, CPSF1 | NOD1 4080/4885NPY4R 3628/4885NPY5R 4211/4885 |
| US-12534722-B2 | Euglobulin-based method for determining the biological activity of defibrotide | FGB, PLG, F2 | NOD1 1460/4885NPY4R 3916/4885NPY5R 3777/4885 |
| US-20220153779-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF TARGET MOLECULES | COMT, TH, AOX1 | NOD1 2919/4885NPY4R 4682/4885NPY5R 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.